Cartesian Therapeutics, Inc. 8-K

What Happened
Cartesian Therapeutics, Inc. filed a Form 8‑K on June 9, 2026 (Item 7.01) disclosing that it issued a press release announcing a strategic licensing agreement with WestGene Biopharma Co. The collaboration is focused on advancing the development of novel in vivo chimeric antigen receptor T‑cell (CAR‑T) therapies targeting autoimmune diseases. A copy of the press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: June 9, 2026 (Form 8‑K, Item 7.01, Regulation FD disclosure).
• Parties: Cartesian Therapeutics, Inc. and WestGene Biopharma Co.
• Focus: Strategic licensing agreement to advance in vivo CAR‑T therapies for autoimmune diseases.
• Exhibit: Press release is included as Exhibit 99.1; the 8‑K does not present financial terms or financial statements.

Why It Matters
This agreement expands Cartesian’s pipeline and collaboration network into in vivo CAR‑T approaches for autoimmune indications, which could broaden its addressable market if programs advance. For investors, the filing signals a strategic partnership but provides no financial terms or immediate financial impact; further details, development milestones, or material financial arrangements would likely appear in future company disclosures. Investors should watch for follow‑up announcements or filings for specifics on terms, timelines, and potential financial implications.